| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
1,353 |
1,326 |
$1.56M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
10,279 |
8,214 |
$1.40M |
| 92134 |
|
13,730 |
13,287 |
$361K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,584 |
2,504 |
$199K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
319 |
308 |
$193K |
| J9035 |
Injection, bevacizumab, 10 mg |
1,793 |
1,657 |
$143K |
| 92235 |
|
1,915 |
1,893 |
$134K |
| 92250 |
|
2,443 |
2,424 |
$96K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
877 |
870 |
$54K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
987 |
968 |
$15K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
14 |
12 |
$11K |
| 67228 |
|
27 |
25 |
$7K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
25 |
25 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12 |
12 |
$999.16 |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
25 |
25 |
$674.19 |
| J7999 |
Compounded drug, not otherwise classified |
12 |
12 |
$0.00 |